European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology
Alexander Enk(Heidelberg University), Detlef Zillikens(University of Lübeck), Stephen Jolles(University Hospital of Wales), Sarolta Kárpáti(Semmelweis University), Giampiero Girolomoni(University of Verona), Lars E. French(University of Miami), Rüdiger Eming(Philipps University of Marburg), Beatrix Volc‐Platzer(Donauspital), Michael Hertl(Universitätsklinikum Gießen und Marburg), Gerhard Fierlbeck(Humboldt-Universität zu Berlin), Kerstin Steinbrink(University of Münster), Georg Stingl(Medical University of Vienna), Eva Hadaschik(West German Heart and Vascular Center Essen)
Cited by 65
Related Papers
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
|Science|1996|1.3k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|597
Regulatory Activity of Autocrine IL-10 on Dendritic Cell Functions
|The Journal of Immunology|2001|553